The U.S. Food and Drug Administration (FDA) last month approved a new indication for somapacitan-beco injection 5 mg, 10 mg, or 15 mg for the treatment of children aged 2.5 years and older who have growth failure due to inadequate secretion of endogenous growth hormone. Novo Nordisk is marketing the treatment as Sogroya® The FDA approval...
Recent insulin price cuts are a dose of good news. In March, Eli Lilly lowered the price on its most popular insulins, with Novo Nordisk and Sanofi following suit shortly thereafter, but only after the $35 monthly price cap for people on Medicare that was mandated by the Inflation Reduction Act. Is this the...
Bigfoot Biomedical today announced the U.S. Food and Drug Administration (FDA) has issued 510(k) clearance for the Android version of the Bigfoot Unity® Mobile App, a necessary component of the Bigfoot Unity® Diabetes Management System. Given that 41 percent of U.S. smartphone users choose Android devices, this clearance enables expanded access to a large group...
Eli Lilly Cuts Insulin Prices by 70% and Caps Patient Insulin Out-of-Pocket Costs at $35 Per Month
[Ed. note: This post has been updated with a comment from Leonard C. Glass, MD, FACE, senior vice president, Lilly Diabetes and Obesity, Global Medical Affairs, Eli Lilly and Company] Eli Lilly and Company today announced price reductions of 70% for its most commonly prescribed insulins and an expansion of its Insulin Value Program that caps...
Out of Practice: Why Retirement Doesn’t Always Mean You Stop Seeing Patients
The Importance of Symptom Control: A Holistic Approach to Treating Acromegaly
Pro Golfer Azahara Muñoz Shares Her Experience with Hashimoto’s Disease